DUI DU WURROREE!

Paralegal National Stage Division
U.S. Appl. No. 10567099 International Appl. No. 4104/170
Application filed by: 20 months 30 months
WIPO PUBLICATION INFORMATION:
Publication No.: WO () / 2053 Publication Language: O English O German O Japanese O Chinese O Korean
Publication Date:
INTERNATIONAL APPLICATION PAPERS IN THE APPLICATION FILE:
International Application (RECORD COPY) PCT/18/331
Article 19 Amendments Respect form PCT/RO/101
PCT/IPEA/409 IPER: O ET O IT O SC O AU PCT/ISA DIO Secreto De la
PCT/PEA/409 IPER was NOT AVAILABLE active since of Disole
Annexes to 409 Search Report References.
Priority Document (s) No Other:
RECEIPTS FROM THE APPLICANT (other than checked above):
Basic National Fee (or authorization to charge) Preliminary Amendment(s) Filed on :
Soletua
Description Claims Abstract Information Disclosure Statement(s) Filed on :
Drawing Figure(s) (# of description) Assignment Document (forwarded to
Assignment Branck 1
Translation of Article 19 Amendments Assignce PG Publication Notice entered and entered: Substitute Sociential Street
Substitute Specification Filed on:
O replaced by Article 14 Amendment
Annexes to 409 O entered O not entered: Oct 479-1-15
O act a page for page substitution O act a page for page substitution O action Declaration (executed)
O so translation O otor: DNA Diskette Sequence Listing
Application Data Sheet
Power of Attorneyl Change of Address
NOTES: Q LA. esed as Specification Q Other:
35 U.S.C. 371 - Receipt of Request (PTO-1390)
Date Acceptable Oath/Declaration Received
Date of Completion of requirements under 35 U.S.C. 371
Tate of Completion of ALL requirements
Inte of Completion of DO/EO 903 - Notification of Acceptance
rate of Completion of DO/ EO 905 - Netification of Missing Requirements
etc of Completion of DO/EO 909 - Notification of Abandonment
etc of Completion of DO/ EO 916 - Notification of Defective Response
ste of Completion of DO/ EO 922 - Notification to Comply w/ Requirements for Potent splications Containing Nucleotide audior Amino Acid Sequence Disclosures

te of Completion of DO/ EO 923